coumarin has been researched along with Epilepsy in 2 studies
2H-chromen-2-one: coumarin derivative
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antiepileptic drugs are the mainstream treatment for epilepsy; however, the drug resistance occurring in 20-30% of patients and side effects of available medications have resulted in a search for natural remedies that can support disease therapy." | 6.61 | Coumarins as potential supportive medication for the treatment of epilepsy. ( Andres-Mach, M; Bryda, J; Szewczyk, A; Zagaja, M, 2019) |
| "Antiepileptic drugs are the mainstream treatment for epilepsy; however, the drug resistance occurring in 20-30% of patients and side effects of available medications have resulted in a search for natural remedies that can support disease therapy." | 2.61 | Coumarins as potential supportive medication for the treatment of epilepsy. ( Andres-Mach, M; Bryda, J; Szewczyk, A; Zagaja, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bryda, J | 1 |
| Zagaja, M | 1 |
| Szewczyk, A | 1 |
| Andres-Mach, M | 1 |
| Sotaniemi, EA | 1 |
| Rautio, A | 1 |
| Bäckstrom, M | 1 |
| Arvela, P | 1 |
| Pelkonen, O | 1 |
1 review available for coumarin and Epilepsy
| Article | Year |
|---|---|
Coumarins as potential supportive medication for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Brain; Coumarins; Disease Models, Animal; Epilepsy; Humans; Seizures | 2019 |
1 other study available for coumarin and Epilepsy
| Article | Year |
|---|---|
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.
Topics: Administration, Oral; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Capsules; Coumarins; Cytochrome P- | 1995 |